Summary
Vertex Pharmaceuticals Inc. reported solid third-quarter 2024 results, driven by strong performance in its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO, which saw a 14% increase in revenue year-over-year. Overall product revenues grew 12% to $2.8 billion. Despite this revenue growth, the company reported a net loss of $1.45 billion for the first nine months of 2024, primarily due to a significant $4.4 billion acquired in-process research and development (AIPR&D) expense related to the acquisition of Alpine Immune Sciences, Inc. in May 2024. This acquisition, while substantial, brings a promising candidate, povetacicept, for IgA nephropathy. The company is also advancing its pipeline with key near-term launch opportunities including vanzacaftor/tezacaftor/deutivacaftor for CF (PDUFA date January 2, 2025) and suzetrigine for acute pain (PDUFA date January 30, 2025). Furthermore, Vertex continues to invest heavily in research and development, with expenses for the first nine months of 2024 totaling $2.6 billion, reflecting its commitment to its diverse pipeline across various therapeutic areas beyond CF.
Financial Highlights
46 data points| Revenue | $2.77B |
| Cost of Revenue | $392.60M |
| Gross Profit | $2.38B |
| SG&A Expenses | $371.80M |
| Operating Expenses | $1.66B |
| Operating Income | $1.12B |
| Net Income | $1.05B |
| EPS (Basic) | $4.05 |
| EPS (Diluted) | $4.01 |
| Shares Outstanding (Basic) | 258.00M |
| Shares Outstanding (Diluted) | 261.00M |
Key Highlights
- 1Product revenues increased 12% to $2.8 billion in Q3 2024, with TRIKAFTA/KAFTRIO revenues up 14% year-over-year, indicating strong demand for its cystic fibrosis treatments.
- 2The company reported a net loss of $1.45 billion for the first nine months of 2024, significantly impacted by a $4.4 billion AIPR&D expense from the acquisition of Alpine Immune Sciences, Inc.
- 3Significant progress is being made on near-term product launches: vanzacaftor/tezacaftor/deutivacaftor for CF has a PDUFA date of January 2, 2025, and suzetrigine for acute pain has a PDUFA date of January 30, 2025.
- 4Research and development expenses increased by 13% to $2.6 billion for the first nine months of 2024, demonstrating continued investment in pipeline development across multiple therapeutic areas.
- 5Cash, cash equivalents, and marketable securities decreased by 18% to $11.2 billion as of September 30, 2024, largely due to the $5.0 billion cash payment for the Alpine acquisition.
- 6CASGEVY, a gene-edited therapy for sickle cell disease and beta thalassemia, received approvals in Switzerland and Canada, with ongoing reimbursement discussions and early access programs being implemented.
- 7The company repurchased $759.2 million of its common stock in the first nine months of 2024, with $1.8 billion remaining authorization under its share repurchase program.